Biotech IPOs raised $7.5 billion across 22 offerings in the first three quarters of 2026, reflecting a revived public-market window even as the biotech index’s recent quarter performance flattened, according to a J.P. Morgan-referenced roundup. The report also highlighted momentum from reverse mergers and the continued concentration of capital in established life-sciences ecosystems.